| mFI-5= 0 (n=397)/% | mFI-5 = 1 (n = 384) /% | mFI-5 ≥ 2 (n = 221)/ % | P Value1 |
---|---|---|---|---|
Age (years) | ||||
 < 65 | 165 (42%) | 114 (30%) | 66 (30%) |  < 0.001 |
 65-74 | 157 (40%) | 135 (35%) | 75 (34%) |  |
 >74 | 75 (19%) | 135 (35%) | 80 (36%) |  |
Sex | ||||
 Male | 222 (56%) | 212 (55%) | 120 (54%) | 0.697 |
 Female | 175 (44%) | 172 (45%) | 101 (46%) |  |
Tumour Site | ||||
 Colon | 209 (53%) | 246 (64%) | 147 (67%) | < 0.001 |
 Rectum | 188 (47%) | 138 (36%) | 74 (34%) |  |
TNM Stage | ||||
 I | 89 (23%) | 98 (26%) | 53 (24%) | 0.072 |
 II | 148 (37%) | 158 (41%) | 98 (44%) |  |
 III | 160 (40%) | 138 (33%) | 70 (32%) |  |
Neo-adjuvant chemotherapy | ||||
 No | 325 (83%) | 338 (88%) | 194 (89%) | 0.024 |
 Yes | 68 (17%) | 45 (12%) | 25 (11%) |  |
MUST Risk 2 | ||||
 Low | 331 (84%) | 302 (81%) | 177 (82%) | 0.630 |
 Medium | 30 (8%) | 36 (10%) | 25 (12%) |  |
 High | 32 (8%) | 36 (10%) | 15 (7%) |  |
BMI (kg/m 2 ) | ||||
 < 20 | 23 (6%) | 28 (7%) | 7 (3%) | 0.034 |
 20-24.9 | 114 (29%) | 122 (32%) | 56 (25%) |  |
 25-29.9 | 147 (37%) | 118 (31%) | 72 (33%) |  |
 ≥ 30 | 113 (29%) | 116 (30%) | 86 (39%) |  |
High SFI | ||||
 No | 81 (20%) | 82 (21%) | 36 (16%) | 0.299 |
 Yes | 316 (80%) | 302 (79%) | 185 (84%) |  |
High VFA | ||||
 No | 111 (28%) | 113 (29%) | 47 (21%) | 0.128 |
 Yes | 286 (72%) | 271 (71%) | 174 (79%) |  |
Low SMI | ||||
 No | 204 (51%) | 184 (48%) | 104 (48%) | 0.407 |
 Yes | 193 (49%) | 200 (52%) | 114 (52%) |  |
Low SMD | ||||
 No | 163 (41%) | 112 (29%) | 59 (27%) | < 0.001 |
 Yes | 234 (59%) | 272 (71%) | 162 (73%) |  |
NLR | ||||
 < 3 | 224 (56%) | 194 (51%) | 105 (48%) | 0.019 |
 3-5 | 116 (29%) | 121 (31%) | 73 (33%) |  |
 > 5 | 57 (14%) | 69 (18%) | 43 (19%) |  |
mGPS | ||||
 0 | 301 (76%) | 271 (70%) | 159 (72%) | 0.028 |
 1 | 50 (13%) | 41 (11%) | 18 (8%) |  |
 2 | 46 (12%) | 72 (19%) | 44 (20%) |  |
SIG | ||||
 0 | 187 (47%) | 155 (40%) | 85 (39%) | 0.006 |
 1 | 107 (27%) | 94 (25%) | 59 (27%) |  |
 2 | 58 (15%) | 80 (21%) | 41 (19%) |  |
 ≥ 3 | 45 (11%) | 55 (14%) | 36 (16%) |  |
Post Operative Complication | ||||
 No | 274 (69%) | 214 (56%) | 126 (57%) | < 0.001 |
 Yes | 123 (31%) | 170 (44%) | 95 (43%) |  |
Thirty-day Mortality | ||||
 No | 395 (99%) | 381 (99%) | 215 (97%) | 0.019 |
 Yes | 2 (1%) | 3 (1%) | 6 (3%) |  |